Invesco S&P SmallCap Consumer Staples ETF (PSCC)

NASDAQ: PSCC · Real-Time Price · USD
36.02
+0.46 (1.29%)
Jun 26, 2026, 4:00 PM EDT - Market closed
1.29%
Assets $32.83M
Expense Ratio 0.29%
PE Ratio 15.14
Shares Out 990,000
Dividend (ttm) $0.60
Dividend Yield 1.68%
Ex-Dividend Date Jun 22, 2026
Payout Ratio 25.39%
1-Year Return +8.07%
Volume 6,024
Open 35.72
Previous Close 35.56
Day's Range 35.72 - 36.10
52-Week Low 30.60
52-Week High 36.66
Beta 0.62
Holdings 28
Inception Date Apr 7, 2010

About PSCC

Fund Home Page

The Invesco S&P SmallCap Consumer Staples ETF (PSCC) is an exchange-traded fund that mostly invests in consumer staples equity. The fund tracks a market-cap-weighted index of consumer staples stocks selected from the S&P SmallCap 600. PSCC was launched on Apr 7, 2010 and is issued by Invesco.

Asset Class Equity
Category Consumer Defensive
Stock Exchange NASDAQ
Ticker Symbol PSCC
ETF Provider Invesco
Index Tracked S&P Small Cap 600 Capped Consumer Staples

Top 10 Holdings

63.46% of assets
Name Symbol Weight
Lamb Weston Holdings, Inc. LW 11.09%
PriceSmart, Inc. PSMT 8.92%
The Campbell's Company CPB 7.91%
The Vita Coco Company, Inc. COCO 6.53%
Cal-Maine Foods, Inc. CALM 6.26%
The Chefs' Warehouse, Inc. CHEF 4.82%
WD-40 Company WDFC 4.82%
Freshpet, Inc. FRPT 4.60%
United Natural Foods, Inc. UNFI 4.33%
The Andersons, Inc. ANDE 4.18%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
Jun 22, 2026 $0.11584 Jun 26, 2026
Mar 23, 2026 $0.13003 Mar 27, 2026
Dec 22, 2025 $0.14135 Dec 26, 2025
Sep 22, 2025 $0.21675 Sep 26, 2025
Jun 23, 2025 $0.20093 Jun 27, 2025
Mar 24, 2025 $0.17199 Mar 28, 2025
Full Dividend History

News

One Biosciences Receives BOOST Funding From Paris-Saclay Cancer Cluster to Advance the First Single-Cell Assay Approach for ADC Therapies

PARIS--(BUSINESS WIRE)-- #adc--One Biosciences receives Paris-Saclay Cancer Cluster (PSCC) BOOST grant to develop first single-cell assay for antibody-drug conjugates therapies.

4 days ago - Business Wire

How To Avoid The Worst Sector ETFs 3Q23

I leverage my firm's data to identify three red flags you can use to avoid the worst ETFs.

3 years ago - Forbes